Quantum Leap Healthcare
3450 California Street
4 articles with Quantum Leap Healthcare
Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers
Athenex’s oral paclitaxel plus encequidar is being evaluated in combination with GSK’s dostarlimab in the neoadjuvant chemotherapy setting
Quantum Leap Healthcare Collaborative Announces the Selection of Byondis' SYD985 in the I-SPY 2 TRIAL for Stage 2/3, High-Risk Breast Cancer
Quantum Leap Healthcare Collaborative™ announced the initiation of an investigational treatment arm with Byondis' [vic-]trastuzumab duocarmazine in the ongoing I-SPY 2 TRIAL™ for neoadjuvant treatment of locally advanced breast cancer.
Quantum Leap Healthcare's I-SPY 2 Investigators, ARDS Experts and COVID R&D Consortium Unite to Bring Success from the I-SPY Adaptive Platform Clinical Trial to COVID-19 ARDS ICU Patients
Quantum Leap Healthcare Collaborative (QLHC), a non-profit organization focused on uniting patient care and research, and sponsor of the adaptive platform I-SPY 2 Trial™, announced today a unique pre-competitive consortium created for an I-SPY COVID Trial to rapidly identify therapies to treat acute respiratory distress syndrome (ARDS) in critically ill COVID-19 patients.
KEYTRUDA's Recent Success in Triple-Negative Breast Cancer Validates I-SPY 2 Adaptive Platform Approach to Phase II Clinical Trials
Quantum Leap Healthcare Collaborative (QLHC) joins Merck in acknowledging the promising data from the KEYNOTE-522 trial. Merck recently announced that the Phase 3 KEYNOTE-522 trial met a primary endpoint, demonstrating statistically significant improved rates of pathological complete response for KEYTRUDA